In compliance with section 17(b) of the Securities Act, we are disclosing that Organicell Regenerative Medicine, Inc. (NASDAQ: OCEL) is a client of TraDigital Marketing Group, Inc. Organicell Regenerative Medicine, Inc. has a 6 month agreement in place, dated August 18, 2022 – February 17, 2023 to compensate TraDigital Marketing Group, Inc. a cash retainer of ninety thousand dollars ($90,000) paid as follows: a monthly cash fee of fifteen thousand dollars ($15,000) for investor relations services and publicly disseminating information about Organicell Regenerative Medicine, Inc. via website, email, and SMS. Organicell Regenerative Medicine, Inc. has paid TraDigital Marketing Group, LLC a one-time stock fee of two million five hundred thousand shares of common stock, restricted under Rule 144, for investor awareness and digital marketing services. The stock is eligible for sale on 02/18/2023. It is TraDigital’s intention to sell all of our shares once the restriction is lifted on 2/18/2023.
Investor awareness and investor relations services and programs are designed to help small-cap companies communicate their investment characteristics. TraDigital Marketing Group, Inc., investor awareness and advisory services include multimedia marketing and other awareness services.